Сравнение
CagriSema vs. Ecnoglutide
Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.
Идентичность
Категория
Метаболизм
Метаболизм
Номер CAS
нет данных
нет данных
Молекулярная масса
нет данных
нет данных
Период полувыведения
нет данных
144 h
Последовательность
нет данных
нет данных
Механизм действия
CagriSema
CagriSema combines two satiety pathways in one weekly injection: the amylin analogue cagrilintide and the GLP-1 agonist semaglutide. Both suppress appetite and food intake — together more than either component alone.
Ecnoglutide
Ecnoglutide is a modified GLP-1(7-37) peptide with an alanine-to-valine substitution at position 8 and an 18-C fatty-acid conjugation at the lysine-30 side chain. It is a so-called biased agonist: at the GLP-1 receptor it preferentially induces cAMP formation while β-arrestin recruitment is reduced. In preclinical models this has been linked to lower receptor internalisation and desensitisation. GLP-1 receptor activation is mechanistically associated with enhanced glucose-dependent insulin secretion, delayed gastric emptying and satiety signalling. The fatty-acid conjugation enables weekly administration via albumin binding.
Доказательная база
Наивысшая доказательность
РКИ на людях
РКИ на людях
Исследования
1
5
из них на людях
1
5
Зафиксированные эффекты
2
4
Открытые противоречия
0
0
Задокументированные нежелательные явления
1
1
Правовой статус
Полные записи
Frequently asked questions
- What is the difference between CagriSema and Ecnoglutide?
- CagriSema is classified as "Метаболизм", while Ecnoglutide is classified as "Метаболизм". CagriSema: CagriSema is a fixed-dose combination of the amylin analogue cagrilintide and the GLP-1 agonist semaglutide (Novo Nordisk), in late-stage development for obesity and type 2 diabetes. Ecnoglutide: Ecnoglutide (XW003) is a long-acting, cAMP-signalling-biased GLP-1 analogue from Sciwind Biosciences. Derived from GLP-1(7-37) with an alanine-to-valine substitution at position 8, it activates the GLP-1 receptor selectively via the cAMP pathway over β-arrestin recruitment. Investigated for weight management and in type 2 diabetes. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, CagriSema or Ecnoglutide?
- The highest available evidence level is "РКИ на людях" for CagriSema and "РКИ на людях" for Ecnoglutide. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of CagriSema and Ecnoglutide in Germany and the United States?
- Германия: CagriSema — Не одобрено, Ecnoglutide — Не одобрено. США: CagriSema — Не одобрено, Ecnoglutide — Не одобрено. These are factual summaries with source and review date on the individual pages.